Ippolito, Alberto
Wang, Hanwen
Zhang, Yu
Vakil, Vahideh
Popel, Aleksander S.
Funding for this research was provided by:
CytomX therapeutics
NIH (R01CA138264)
Article History
Received: 25 October 2023
Accepted: 19 May 2024
First Online: 10 June 2024
Declarations
:
: A.I. is currently an AstraZeneca PLC employee. V.V. is a CytomX Therapeutics employee. A.S.P. is a consultant to J&J/Jenssen, Incyte, and AsclepiX Therapeutics. The other authors declare no competing interests relevant to this study.
: A.I. is currently an AstraZeneca PLC employee. V.V. is a CytomX Therapeutics employee. A.S.P. is a consultant to J&J/Jenssen, Incyte, and AsclepiX Therapeutics. The other authors declare no competing interests relevant to this study.